QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (1280)	10/16/2003 1:42:00 AM
From: Sultan	of 1321

Visudyne(TM) approved in Japan for treatment of age-related macular degeneration (AMD) Thursday October 16, 1:30 am ET VANCOUVER, CANADA and BASEL, SWITZERLAND, Oct. 15 /CNW/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News) and Novartis Ophthalmics, the eye health unit of Novartis AG (NYSE: NVS - News) announced today that health authorities in Japan have approved Visudyne(R) (verteporfin) for the treatment of the "wet" form of age- related macular degeneration (AMD), the leading cause of blindness in people over age 50. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next